FDA Approves Addyi for Women Over 65 to Boost Libido

U.S. health officials have expanded the approval of the libido-enhancing pill, Addyi, to include women over the age of 65 who have gone through menopause. The announcement from the **U.S. Food and Drug Administration (FDA)** on March 18, 2024, marks a significant shift in the medication’s application, which was initially approved in **2015** for premenopausal women experiencing emotional distress due to low sexual drive.

The pill, produced by **Sprout Pharmaceuticals**, is designed to address hypoactive sexual desire disorder, a condition affecting many women and recognized since the 1990s. Despite its intended benefits, Addyi has faced criticism due to its side effects, which include dizziness and nausea. Moreover, the drug carries a boxed warning—the most severe safety notice from the FDA—indicating that mixing the pill with alcohol can lead to dangerously low blood pressure and fainting.

Challenges and Controversies Surrounding Addyi

Initially expected to be a blockbuster treatment, Addyi’s sales have been limited, partly because of its side effects and the complexities surrounding the diagnosis of low libido in women. Doctors must evaluate various factors that may affect sexual desire, particularly post-menopause, when declining hormone levels can result in numerous biological changes and health issues. Before prescribing Addyi, healthcare professionals typically rule out other potential causes, including relationship difficulties and mental health disorders.

Sprout Pharmaceuticals’ CEO, **Cindy Eckert**, expressed optimism about the FDA’s decision, stating that it reflects a decade of advocacy aimed at reshaping the perception and prioritization of women’s sexual health. The company’s press release emphasized the importance of expanding treatment options for women facing sexual health issues.

The initial approval of Addyi was met with resistance, as the FDA rejected the drug twice before finally granting approval in **2015**. This decision followed a lobbying effort led by the company and its supporters, who framed the limited options for women’s sexual health as a matter of women’s rights. In **2019**, the FDA approved a second medication for low female libido, an on-demand injection that operates on different neurological pathways.

The Broader Context of Women’s Sexual Health

Despite the advances made in treating hypoactive sexual desire disorder, the diagnosis remains controversial. Some psychologists argue that low libido should not be classified as a medical condition, complicating the landscape for women seeking help.

The condition is believed to impact a significant portion of American women, with surveys indicating varying degrees of prevalence. As research into female sexual dysfunction grows, the challenges of creating effective treatments continue to prompt discussions about gender equity in healthcare.

According to the **Associated Press**, the health and science department is supported by the **Howard Hughes Medical Institute’s** Department of Science Education and the **Robert Wood Johnson Foundation**. The information presented here comes from a variety of credible sources and underscores the ongoing evolution of women’s health treatments.